Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 101,000 Shares

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 101,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $244.30, for a total transaction of $24,674,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Beigene Price Performance

Shares of NASDAQ:ONC opened at $262.21 on Thursday. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a one year low of $126.97 and a one year high of $287.88. The firm has a market capitalization of $25.66 billion, a price-to-earnings ratio of -31.82, a PEG ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. Sell-side analysts forecast that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Macquarie raised their price objective on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $207.00 to $320.00 in a report on Monday.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.